drugset / Trial / NCT04441788

A Study to Assess the Safety, Tolerability, and Efficacy of ION-827359 in Participants With Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD) With Chronic Bronchitis (CB)

NCT04441788 ↗

Phase 2 Terminated 60 enrolled Ionis Pharmaceuticals, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study was to evaluate the effect of ION-827359 on forced expiratory volume in 1 second (FEV1) in participants with mild to moderate COPD with CB.

Timeline

Start
2020-12-22
Primary completion
2021-04-27
Completion
2021-08-09

Outcome

Outcome not reported

Stopped (Business): “Business Decision to Terminate Study”

Drugs

EvaluationDrugModalityDoseRoute
Subject COFIRASERSEN Unknown 37.5 mg Inhaled
Subject COFIRASERSEN Unknown 75 mg Inhaled

Indications